Ra223DichlorideInjectionQC

Ra-223 Dichloride Injection QC — Quality control of Ra-223 Dichloride injection

ℹ️ Utility checks critical parameters of Ra-223 Dichloride:

• Radionuclidic purity (≥99.9%)
• Ac-227 impurity (<0.001%) — CRITICAL!
• Ra-224 impurity (<0.01%)
• pH, osmolality, endotoxins, sterility

⚠️ CRITICAL: Ac-227 (T½=21.8 years) creates lifelong radiation burden!

Ra-223 is used for targeted alpha therapy of bone metastases.

Drug mimics calcium and incorporates into bone tissue.

Usage

Ra223DichlorideInjectionQC.exe → demo mode (console output)

Ra223DichlorideInjectionQC.exe input.csv output.json → evaluate your data

Input format

BatchNumber,RadionuclidicPurityPercent,Ac227ImpurityPercent,Ra224ImpurityPercent,RadiochemicalPurityPercent,pH,Osmolality_mOsm_per_kg,EndotoxinsEU_per_mL,SterilityTest,ActivitykBq_per_mL,ParticulateMatterCount,AlphaRecoilDaughtersPercent

Example

RA223-INJ-2026-001,99.95,0.0001,0.005,99.0,6.5,300.0,5.0,0,1000.0,10.0,0.1

— WHY IS THIS NEEDED?

Ra-223 Dichloride (Xofigo) is first approved alpha-emitter for systemic therapy.

• Mimics calcium and selectively accumulates in areas of increased bone turnover (metastases).
• Emits 4 alpha particles in decay chain, providing high local dose.
• Half-life 11.4 days.
• Produced from Ac-227/Ra-223 generator.

⚠️ CRITICAL:

• Radionuclidic purity ≥99.9% — guarantee of absence of other radium isotopes.
• Ac-227 impurity <0.001% — Ac-227 is parent nuclide with 21.8-year half-life. Its entry into body is unacceptable due to long-term toxicity.
• Ra-224 impurity <0.01% — Ra-224 has different decay profile and may distort dosimetry.
• Radiochemical purity ≥95% — Ra must be in free Ra2+ ion form for bone incorporation.
• pH 6.0-8.0 — physiological range.
• Osmolality 250-350 mOsm/kg — blood isotonicity.
• Endotoxins <175 EU/mL — standard for parenteral drugs.
• Sterility — MANDATORY.
• Particle control — important for IV injections.

Key features

• Strictest control of Ac-227 impurity characteristic of generator production.
• Assessment of radiochemical form (free ion).
• Osmolality and pH check for administration safety.
• Compliance with GMP and Pharmacopoeia requirements for Ra-223.
• Comprehensive safety check (endotoxins, sterility, particles).

Critical parameters

• Radionuclidic purity: ≥99.9%
• Ac-227 impurity: <0.001%
• Ra-224 impurity: <0.01%
• Radiochemical purity: ≥95.0%
• pH: 6.0–8.0
• Osmolality: 250–350 mOsm/kg
• Endotoxins: <175 EU/mL
• Sterility: no growth
• Particles (>10 μm): <6000

💡 Usage tips:

1. Radionuclidic purity determined by gamma spectrometry.

2. Ac-227 impurity controlled through long-term decay observation or mass spectrometry.

3. Drug is ready-to-use and does not require dilution.

4. Due to alpha decay, gaseous radon (Rn-219) accumulation is possible, requiring ventilation during work.

5. Ra-223 is rapidly cleared from blood, so drug quality is critical for delivering dose specifically to bones.

⚠️ Note: Ra-223 represents unique class of therapeutic agents. Quality control here focuses not so much on chemical stability of complex (as with chelates), but on purity of radionuclide itself, as any long-lived impurity nuclide becomes part of patient's skeleton forever.